Cardiology Testing April 25, 2024
The MI Overdiagnosis Problem April 25, 2024
Over 750k people are diagnosed with myocardial infarction in the United States every year, and a new JAMA paper suggests that far more of those patients are incorrectly diagnosed than many might expect.
Atrial Fibrillation April 22, 2024
Atrial Fibrillation’s Downstream Consequences April 22, 2024
A BMJ study out of Denmark provided alarming new insights into atrial fibrillation’s impact on patients’ future cardiovascular health, while highlighting the need to improve post-AFib heart failure and stroke prevention.
Artificial Intelligence April 18, 2024
Cedars-Sinai Detects AFib with Echo AI April 18, 2024
A Cedars-Sinai-led team developed an echocardiography AI model that accurately detects patients with atrial fibrillation - including asymptomatic patients - potentially revealing a new “opportunistic screening” method to drive earlier AFib detection and treatment.
Cardiology Policy April 15, 2024
Cardiology’s Industry Payments Problem April 15, 2024
Healthcare watchdogs set their sights on cardiology’s industry payments last week, revealing some key examples of how vendor payments could influence the approval and adoption of major cardiovascular technologies.
Cardiology April 11, 2024
Cardiac Wire’s Top 8 Takeaways from ACC 2024 April 11, 2024
The ACC 2024 meeting is now complete, after over 17,000 cardiology professionals converged in Atlanta to witness cardiovascular medicine evolve in front of their eyes. Among dozens of highlights, here are the Cardiac Wire’s eight biggest trends emerging from ACC24.
Gene Editing April 8, 2024
Verve Therapeutics’ PCSK9 Pivot April 8, 2024
Verve Therapeutics’ stock price and gene editing momentum both took major dips last week, after the company announced that it paused its Heart-1 trial evaluating its VERVE-101 PCSK9 gene therapy, and revealed that it will now prioritize the development of its VERVE-102 therapy.
Artificial Intelligence April 4, 2024
Chest X-Rays’ Cardiovascular Screening Potential April 4, 2024
There are over 70 million chest X-rays performed in the U.S. every year, and a pair of new studies highlighted how AI could be used to “opportunistically screen” these exams for undetected cardiovascular disease.
Cardiology April 1, 2024
Statins’ Diabetes Risks and Benefits April 1, 2024
A new Lancet study brought statins’ diabetes risks back into the headlines, showing that statins do indeed drive significant increases in new diabetes diagnoses, while arguing that statins’ cardiovascular benefits still far outweigh their diabetes risks.
Hypertension March 28, 2024
Merck’s Sotatercept Lands PAH Approval March 28, 2024
Patients with pulmonary arterial hypertension suddenly have a new and potentially powerful treatment option available to them, following the FDA approval of Merck’s sotatercept-csrk, which will be marketed as Winrevair in the US.
Obesity Care March 25, 2024
Weight Loss Drugs Land Medicare Coverage for Cardiovascular Events March 25, 2024
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”... like cardiovascular disease.
Preventive Cardiology March 21, 2024
Questioning Intermittent Fasting’s Cardiovascular Impact March 21, 2024
A new AHA study shocked the world this week, suggesting that intermittent fasting might significantly increase people's risk of cardiovascular death, sparking a wave of media coverage, and frenzy of criticisms from the cardiologist and scientific communities.
Pharmaceuticals March 18, 2024
Silence Therapeutics’ Zerlasiran Shows LP(a) Potential March 18, 2024
Silence Therapeutics’ zerlasiran continued to demonstrate its lipoprotein(a) impact, as topline Phase 2 data showed that the injectable siRNA slashed LP(a) levels by over 90% through 36 weeks.
Obesity Care March 14, 2024
Wegovy Gains Expanded Approval for CVD Risk Reduction March 14, 2024
Wegovy approved for CVD risk reduction, nanopainting anti-blockage drugs, and plenty of other cardiology news.
Preventive Cardiology March 11, 2024
Microplastics, Nanoplastics, and Major Cardiac Events March 11, 2024
A landmark NEJM study revealed that many patients with carotid artery disease might have microplastics and nanoplastics embedded in their carotid plaque, and those patients have a massive 4.5-fold greater risk of heart attack, stroke, or death within three years.
Heart Failure March 7, 2024
Endotronix Cordella Shows HF Impact in PROACTIVE-HF Trial March 7, 2024
Endotronix took a big step toward its vision for pulmonary artery pressure-based heart failure medication optimization, releasing positive results from its Cordella Sensor’s PROACTIVE-HF pivotal trial.
Surgeries & Interventions March 4, 2024
Boston Scientific AGENT Drug-Coated Balloon Lands Long-Awaited FDA Approval March 4, 2024
AGENT DCB lands FDA approval, the benefits of ECG for low-risk patients, and plenty of other cardiology news.
Preventive Cardiology February 29, 2024
Lipoprotein(a)’s High (and Uneven) Cardiovascular Risks February 29, 2024
Harvard researchers strengthened the link between high Lipoprotein(a) levels and greater risks of future cardiovascular events, including among patients who haven’t been diagnosed with ASCVD.
Imaging February 26, 2024
Philips Launches Radiation-Free LumiGuide Navigation System February 26, 2024
Philips made interventional imaging headlines last week, announcing the US and European launch of its LumiGuide interventional imaging system, positioning it as a key step toward “bringing healthcare closer to entirely radiation-free surgery.”
Heart Failure February 22, 2024
Reprieve Cardiovascular Looks to Transform ADHF Decongestion Management February 22, 2024
Reprieve Cardiovascular emerged this week, announcing a hefty $42M Series A round and an even bigger mission to “transform the standard of care” for patients with acute decompensated heart failure.
